The Potential for Kratom as an Antidepressant and Antipsychotic

Lindsay E. Johnson, Lilian Balyan, Amy Magdalany, Fizza Saeed, Robert Salinas, Starla Wallace, Charles A. Veltri, Marc T. Swogger, Zach Walsh, and Oliver Grundmann

INTRODUCTION

Mitragyna speciosa, also known as kratom, is a plant within the coffee family (Rubiaceae) native to Southeast Asia and Thailand [1]. Kratom has been used in Southeast Asia for centuries as a stimulant, treatment for diabetes, diarrhea, improved circulation within the body, and to extend the duration of sexual intercourse [2,3]. The leaves of Mitragyna speciosa have been shown to cause opioid-like and stimulant responses upon ingestion, and
in the regions of its traditional use kratom is used as a
treatment for pain management and opioid withdrawal
[1,4].

The observational science on the experience of kra-
tom users indicates several reliable psychoactive effects. At
lower doses, an increase in alertness, motivation, and
sexual desire are commonly reported. At higher doses, op-
dioid dependent users report improvements in opioid
withdrawal symptoms and a decreased desire to use
other illicit substances, suggesting kratom’s potential as
a harm reduction agent for people with substance use
disorders. Another widely reported reason for kratom use
is pain management [5-7]. Whereas fewer studies have
examined kratom’s use for negative mood states and con-
ditions, a recent systematic review of 13 observational
studies indicated that kratom is also being used to self-
treat negative affect, most frequently anxiety and depres-
sion, with users reporting generally positive results [8].
Based on prior and recent studies involving kratom and
similarities between kratom and several substances with
antidepressant and anxiolytic properties, we examine
literature germane to estimating kratom’s potential utility
as a treatment for psychiatric symptoms [9].

More than 40 alkaloids have been identified to date
from kratom leaves, of which mitragynine, corynanthei-
dine, and 7-hydroxymitragynine (7-HMG) are known to
produce a range of pharmacological effects in humans
[10,11]. The proposed major pharmacologically active
compounds with opioid-like activity are mitragynine
and 7-HMG. These are indole alkaloids exclusive to
Mitragyna speciosa that act as partial biased agonists at
mu-opioid receptors activating only the G-protein signal-
ing pathway [1]. Importantly, these compounds operate
without recruiting beta-arrestin 2, which is associated
with a range of commonly reported undesirable effects
such as respiratory depression, constipation, and depen-
dence [1,12]. The major constituent, mitragynine, is also
a proposed agonist at the adrenergic alpha-2 receptor
[13], a mechanism that is currently utilized in opioid
withdrawal therapies with mechanism of action similar
to clonidine, a selective alpha-2 receptor agonist. This
activity may therefore allow for the reduction of with-
drawal symptoms and have the ability to decrease opioid
cravings. Unlike 7-HMG, mitragynine has been found to
lack additive properties [4]. 7-HMG is present in lower
concentrations than mitragynine, but displays a higher
potency. While kratom is most commonly known for its
affinity to opioid receptors, it also has affinity to serotonin
and dopamine receptors [13,14], signaling its potential
for treating depression, anxiety, and psychosis.

METHODS
Search Strategy

This narrative literature review addresses the current
scientific knowledge of kratom and its potential use as
an antidepressant, anxiolytic, and antipsychotic based
on structural similarities of its indole alkaloids, in vitro
receptor binding studies, animal experiments, and human
reports. Human data was obtained from surveys and
observational studies since, to date, there are no clinical
studies on kratom or any of its constituents. The 32 rel-
vant articles included are from peer-reviewed journal
articles obtained through electronic databases (PubMed,
ScienceDirect, and Google Scholar). Keywords used to
execute the searches included the following: “kratom,”
“Mitragynine,” “Mitragyna speciosa,” “7-hydroxymiti-
tragynine,” and “indole alkaloids.” Articles included
discuss the pharmacology of either kratom preparations
or the isolated Mitragyna alkaloids and their potential
adverse effects as it relates to stimulant, antidepressant,
anxiolytic, antipsychotic, and opioid-like effects, in which
approximately 70 articles were found. Once the informa-
tion was identified in literature searches, more specific
searches were conducted focusing on the following: (i)
indole alkaloids and pharmacological activity (ii) antide-
pressant effects and kratom (iii) antipsychotic effects and
kratom. Forty-three articles were analyzed and retained
for further review. We excluded studies that did not in-
clude information directly related to the antidepressant,
anxiolytic, or antipsychotic activity of Mitragyna spe-
ciosa or its constituents in vitro, in animals, or in human
studies for inclusion in the review of the study methods.
Finally, 32 articles met all criteria and were examined for
data relevant to kratom and antipsychotic, antidepressant,
or anxiolytic effects.

ANTIDEPRESSANT AND ANTIPSYCHOTIC
EFFECTS OF KRATOM AND MITRAGYNNINE

Indole alkaloids have been used for, and continue
to show promise as, therapeutic drugs [15]. These com-
pounds exhibit pharmacological activity through inter-
actions with dopamine, serotonin, and norepinephrine
receptors [16]. They have been developed into useful
therapies for migraine, depression, and schizophrenia.
Mitragyna speciosa contains indole alkaloids that target
serotonin and dopamine signaling pathways and show
promise as a treatment for depressive and psychotic dis-
orders. While mitragynine is most prevalent in the leaves,
similar indole alkaloids, such as paynantheine and spe-
ciociliatine, are also present [10].

Antipsychotics can be grouped into two major class-
es, typical and atypical. Typical agents such as haloperi-
dol and chlorpromazine, are thought to work by inhibit-
ing \(D_2\) dopamine receptors to treat the positive symptoms of psychosis such as hallucination and delusion while atypical antipsychotics treat both positive and negative symptoms, the latter including decreased motivation and ability to feel pleasure, as well as social withdrawal via inhibition of \(D_2\) dopamine, alpha-2 adrenergic and serotonin receptors (5-HT\(_{2A}\)). While both of these classes of medications can be especially helpful in the management of psychosis, the side effects present a wide range of complications for the patient, some of which include tardive dyskinesia, dystonia, weight gain, and agranulocytosis to name a few [17]. To date, these adverse effects have not been observed with the use of kratom or its isolated alkaloid mitragynine in animals or humans.

A 2016 study using \textit{in vivo} and \textit{ex vivo} models showed that mitragynine has inhibitory effects on the same receptors to which atypical antipsychotics bind. Mitragynine has inhibitory effects on receptors similar to current medications that are used to treat psychosis which also inhibit \(D_2\) dopamine receptors [17]. This study also conducted research on the effect of mitragynine as an antipsychotic in mice in whom psychosis was induced by using apomorphine, a dopamine agonist, which manifested in abnormal cage-climbing behavior. It was then determined that 75 to 100 mg/kg of a methanolic kratom leaf extract containing 4.4% mitragynine was able to significantly decrease psychotic symptoms. While mitragynine has affinity to dopamine receptors assisting in the alleviation of positive symptoms (auditory, visual, and tactile hallucinations, delusions), it is suggested that mitragynine would also have the ability to reduce negative symptoms (alopecia, avolition) through antagonism at serotonin 5-HT\(_{2A}\) and 5-HT\(_{2C}\) receptors.

In the screening of antidepressant compounds, two methods are commonly used to assess the effectiveness of compounds in mice: the forced swimming test (FST) and the tail suspension test. The forced swimming test is used to assess the absence of escape-oriented behaviors which is timed when the mouse becomes immobile, defined as motionless except for the mouse keeping their head above water. The tail suspension test involves attaching tape on the mouse’s tail to keep it suspended above the ground. Immobility is again tested by the time the mouse is completely immobile and motionless [3]. In a study in which two different doses of mitragynine and a control were injected intraperitoneally, both the forced swimming test and the tail suspension test indicated that both the 10 mg/kg and 30 mg/kg doses of mitragynine significantly reduced immobility time when compared to the control. In addition, like fluoxetine and amitriptyline, two common antidepressant drugs, mitragynine produced similar responses in immobility time indicating that in this context mitragynine may be effective as an antidepressant. It was also found that mitragynine decreased levels of blood cortisol similar to the effects of fluoxetine and amitriptyline in these tests [3]. Clinical research indicates a positive correlation between cortisol levels as a representation of stress and the risk of developing major depressive disorders [18].

A separate animal study conducted in 2006 on mitragynine in adult male Wistar rats and male ICR mice, found a single intraperitoneal administration of the alkaloid-rich fraction of kratom (containing 60% mitragynine) in doses of 60 mg/kg and 90 mg/kg to mice also resulted in significantly decreased immobility time in the FST [19] without affecting locomotor activity, which is an indicator of stimulant effects. The same study identified that both the antinociceptive and antidepressant effects of kratom may in part be mediated through activation of the c-Fos pathway and higher FOS protein levels in the dorsal raphe nuclei [19]. The Dorsal raphe nucleus presents with a high density of serotonin nuclei and innervations to the forebrain which has been linked to its central role in depression. A major limitation of these two studies is the intraperitoneal route of administration of mitragynine and kratom circumventing the gastrointestinal tract thus excluding potential metabolism by CYP enzymes and intestinal bacteria.

Two other animal studies in rats and mice investigated the effect of orally administered kratom on mitigation of ethanol withdrawal symptoms compared to fluoxetine [20,21]. Ethanol withdrawal in previously ethanol-dependent animals is a commonly employed model for the induction of depression and subsequent evaluation of antidepressant activity of new drugs [22]. The proposed neuropathological changes leading to reductions in monoamine neurotransmitters as well as other pathways associated with depressive disorders are reproducible in this model. In both studies, the alkaloid fraction of kratom reduced ethanol withdrawal symptoms in a similar manner to fluoxetine by reducing locomotor hyperactivity. A distinction between the alkaloid fraction of kratom and fluoxetine was observed via EEG in rats. While fluoxetine and other selective serotonin reuptake inhibitors (SSRIs) are known to suppress REM sleep, the alkaloid fraction of kratom did not affect any REM parameters following oral administration. As shown in [3], mitragynine may have similar impact on animal behavior to that of fluoxetine in studies using both the forced swimming test and tail suspension test. This similarity in action suggests the potential value of kratom as an antidepressant.

While mitragynine is primarily recognized for its action on opioid receptors, it does not structurally resemble other medications in the opioid family. This indicates mitragynine may have a broader receptor specificity than originally expected [23]. Mitragynine, fluoxetine, DMT, LSD, and psilocybin all interact with serotonin receptors, while LSD also has an affinity to \(D_2\) receptors. The affin-
ity of mitragynine to the 5-HT\textsubscript{2C} receptor, and affinity to D\textsubscript{3} receptors may indicate how this compound could be an effective antidepressant, as fluoxetine is an inhibitor at this receptor subtype as well.

**USER EXPERIENCE AND CLINICAL REPORTS WITH KRATOM**

A range of personal experiences have been described by kratom users at varying doses. Low doses generally provide a motivational and stimulant effect and may thus be helpful in work settings. Higher doses are reported to increase relaxation and calm. Users describe increased sociability and empathy. While visual alterations, gastrointestinal (GI) upset, dizziness, and vomiting have been reported as common side effects, GI upset and dizziness are most commonly observed if kratom is taken concomitantly with other substances [24,25]. Users from various backgrounds have reported feeling happiness, well-being, mellowness, being able to relax, a mental calm with no loss of clarity, having more energy, increased desire to work, and a strong desire to communicate with loved ones [25]. Users have reported the kratom experience as akin to a mild psychedelic experience, including close-eye visual patterns, a mild expansion consciousness relative to visual and auditory stimuli. These experiences [25] may indicate a similarity in the mechanisms (i.e. 5-HT) of kratom to that of psychedelic substances such as LSD and DMT.

Although no clinical study has evaluated the antidepressant effects of kratom, or any of its constituents to date, several online and in-person surveys document the reasons and benefits that kratom users report [7,8,24,26,27]. In a 2016 online survey conducted among 8,049 current kratom users, 58% reported use for self-treatment of a mental or emotional disorder [24]. Among those taking kratom to self-treat a mental or emotional disorder, females were more likely to take kratom for such conditions, while those aged 41 or older were less likely to consume for these reasons. In a subsequent analysis of the data, 66.5% of users who consumed kratom to self-treat a mental or emotional disorder rated their health as “good” or “very good” [7]. In the same publication, the correlation between a reported diagnosis of depression and the use of kratom for self-treatment of a mental or emotional disorder was significantly higher for women and inversely related with age. Income was found to have a negative correlation with a diagnosed depressive disorder and with the use of kratom for self-treatment.

In another 2019 online survey including 3,024 former and current kratom users, similar demographics were reported with 66.4% of current kratom users selecting anxiety or depression as one of the impelling causes for the use of the product, while 20.2% disclose it as the main motivation [27]. In contrast, only 14.5% of current users listed relief of withdrawal symptoms as one reason, and 2.2% chose it as the main reason for consuming kratom products. The most common reason for consuming kratom was pain relief in both current and past kratom users.

A 2017 anonymous survey of 500 kratom users and a 2015 quantitative analysis of experiences of 161 kratom users indicated that kratom products are used as a mitigation strategy to reduce opioid withdrawal symptoms, which often involve states of depression and anxiety [25,26]. In general, people with recent harmful opioid use are more likely to use kratom as a harm reduction strategy than those who use other illicit drugs. A third of the respondents in this survey who had used kratom to mitigate withdrawal symptoms indicated that they would take the product again [26]. From these initial survey studies kratom is primarily used to prevent opioid withdrawal effects and as a self-treatment of a mental or emotional disorder which include depression and anxiety.

**PHARMACOKINETICS**

Of all *Mitragyna speciosa* alkaloids, mitragynine makes up 66% of them while paynantheine accounts for 9%, followed by speciociliatine at 7%, and 7-HMG at 2% of the total alkaloid content. The additional alkaloids are only found in miniscule amounts [28]; however, of the raw leaf material, mitragynine only accounts for about 2%, illustrating the differentiation between the alkaloid fraction often reported in the literature and actual total leaf material amount that is ingested [29]. Mitragynine has a low oral bioavailability of 3% [28-30], which may be a result of high first-pass metabolism via cytochrome P450 (CYP) enzymes in the intestines and the liver, as well as low solubility in the intestinal lumen leading to reduced absorption. Mitragynine has a short half-life of approximately 3 hours after injection of the compound but presents with a long terminal half-life of approximately 29 hours following oral administration, suggesting a biphasic distribution model [31,32]. The pharmacokinetics in a small study of 10 chronic users show kratom, more specifically the major constituent mitragynine, has a two-compartment model with a half-life of approximately one day [2]. Metabolism of mitragynine mainly occurs in the liver where *in vitro* experiments indicate that mitragynine interacts with other medications and substances via CYP enzymes [9]. Mitragynine and 7-HMG may inhibit the activity of CYP2D6 and CYP3A4. Moderate inhibitory effects are seen with CYP1A2 and mild inhibition of CYP2C19. *In vitro*, it has been shown that mitragynine and 7-HMG also act as inhibitors of P-glycoprotein (P-gp). Although the clinical significance of the inhibitory effect on CYP enzymes by kratom and its alkaloids has not been determined, kratom
is often reported together with drugs that are substrates for CYP3A4 (alprazolam, carbamazepine, phenobarbital, phenytoin, quetiapine, oxycodone), CYP2D6 (amitriptyline, fluoxetine, haloperidol, codeine), and CYP1A2 (theophylline, clozapine) [2,9,33].

P-gp is a drug transporter expressed in the endoplasmic reticulum with very broad specificity. This protein has the ability to pump xenobiotics out of the cell to reduce absorption of the substances into the systemic circulation or from crossing the blood-brain barrier. A 2019 study determined mitragynine to be an inhibitor of P-gp, which could lead to significant drug-drug interactions between kratom and other substances [33].

TOXICITY

The toxicity of kratom has been studied for total alkaloid extracts in mice which found an LD₅₀ of 173 mg/kg [34] and 592 mg/kg [35], and for methanolic extracts in mice, an oral LD₅₀ of 4,900 mg/kg was reported [34]. In a study of rats receiving mitragynine at various doses for 5 days per week for 6 weeks, minor changes in body weight and liver and kidney weights were observed, but no other behavioral or physiological effects were noted. In dogs, no adverse effects were observed after 3 weeks; however, there were changes in blood chemistry, liver cell morphology, and lymphatic hyperplasia after an additional 3-week dosing period [35]. A 2013 study in rats produced similar results with low and intermediate doses showing little sign of toxicity, but induced hematological and liver and brain histopathological changes suggestive of toxicity at a higher dose [36].

In very high doses of mitragynine administered to various animal species (the human equivalent of more than 15 g/dose), there were no acute deaths or significant effects of toxicity, however in humans [37], unlike opioids, there have been no reported effects of respiratory depression or opioid toxic syndrome with the use of kratom alone. Hypothyroidism and intrahepatic cholestasis have been reported co-existent with kratom use, but these data are from case studies and thus provide little evidence that kratom caused the events due to limits on internal validity [1,36,38]. When taken orally in single doses up to 5 g, the main side effects were nausea, itching, loss of appetite, and increased urination [25,38]. When taken at increased doses of 8g or more, adverse effects included constipation, sedation, hypotension, sweating, dry mouth, and tachycardia [24].

CONCLUSIONS

Kratom as a traditional medicine has become widely known and used as a supplement for the self-treatment of a variety of disorders. Because of its proposed stimulant effects and self-reported benefits, kratom might induce increased behavioral activation among people with depression, anxiety, and psychosis, leading to the improvements of mental health conditions. The low toxicity of kratom and its constituents indicate this may be beneficial for the development of a safe and tolerable antidepressant/antipsychotic. One potential drawback of the use of kratom is dependency and addiction to the product. Because there is currently no accepted medical indication for kratom or its alkaloids and a potential for dependency, the US Drug Enforcement Administration (DEA) regards it as a "drug of concern" [5]. The US Food and Drug Administration (FDA) furthermore has classified mitragynine and alike indole alkaloids as opioids which complicates clinical trial approval to evaluate effects of kratom and its constituents in humans [5]. However, kratom as well as mitragynine require more research to determine the most effective dosing for its psychoactive properties, while reducing addiction liability.

In conclusion, the research conducted on kratom, especially its major constituent mitragynine, shows promise for the possible future use of kratom as an antidepressant and antipsychotic. Additional research needs to be conducted on the mechanism of action of kratom and its constituents to analyze the mechanism in which it elicits antidepressant and antipsychotic effects. We suggest the interaction of kratom on both dopamine and serotonin receptors may lead to a decrease in psychosis, especially due to the interaction of the dopamine receptor, as demonstrated by other antipsychotic medications interaction with this receptor. Depression is likely decreased due to the interaction on serotonin receptors, as seen with the interaction of other antidepressants on serotonin receptors. Due to mitragynine’s affinity to dopamine and serotonin receptors this compound shows significant promise as a lead drug or treatment for psychiatric disorders.

REFERENCES

1. Prozialeck WC, Jivan JK, Andurkar SV. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc. 2012;112(12):792-9. PubMed PMID: 23212430.

2. Kruegel AC, Gassaway MM, Kapoor A, Varadi A, Majumdar S, Filizola M, et al. Synthetic and Receptor Signaling Explanations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators. J Am Chem Soc. 2016;138(21):6754-64. Epub 2016/05/19. doi: 10.1021/jacs.6b00360. PubMed PMID: 27192616.

3. Idayu NF, Hidayat MT, Moklas MA, Sharida F, Raudzah AR, Shamima AR, et al. Antidepressant-like effect of mitragynine isolated from Mitragyna speciosa Korth in mice model of depression. Phytotherapy. 2011;18(5):402-7. Epub 2010/09/28. doi: 10.1016/j.phymed.2010.08.011. PubMed PMID: 20869223.
4. Mohamad Zuldin NN, Said IM, Mohd Noor N, Zainal Z, Jin Kiatt C, Ismail I. Induction and Analysis of the Alkaloid Mitragynine Content of a Mitragyna Speciosa Suspension Culture System Upon Elicitation and Precursor Feeding. The Scientific World Journal. 2013;2013. doi: 10.1155/2013/209434. PubMed PMID: 24065873.

5. White CM. Pharmacologic and Clinical Assessment of Kratom: An Update. Ann J Health Syst Pharm. 2019;76(23). doi: 10.1093/ajhp/zxz221. PubMed PMID: 31626272.

6. Singh D, Yeou Chear NJ, Narayanan S, Leon F, Sharma A, McCurdy CR, et al. Patterns and Reasons for Kratom (Mitragyna Speciosa) Use Among Current and Former Opioid Poly-Drug Users. Journal of ethnopharmacology. 2019. doi: 10.1016/j.jep.2019.112462. PubMed PMID: 31816368.

7. Bath R, Bucholz T, Buros AF, Singh D, Smith KE, Veltri 6. Singh D, Yeou Chear NJ, Narayanan S, Leon F, Sharma A, McCurdy CR, et al. Patterns and Reasons for Kratom (Mitragyna Speciosa) Use Among Current and Former Opioid Poly-Drug Users. Journal of ethnopharmacology. 2019. doi: 10.1016/j.jep.2019.112462. PubMed PMID: 31816368.

8. Swogger MT, Walsh Z. Kratom use and mental health: A systematic review. Drug Alcohol Depend. 2018;183:134-40. Epub 2017/12/19. doi: 10.1016/j.drugalcdep.2017.10.012. PubMed PMID: 29248691.

9. Meireles V, Rosado T, Barroso M, Soares S, Goncalves J, Luis Â, et al. Mitragyna speciosa: Clinical, Toxico logical Aspects and Analysis in Biological and Non-Biological Samples. Medicines (Basel, Switzerland). 2019;6(1). doi: 10.3390/medicines6010035. PubMed PMID: 30836609.

10. Hamid HA, Ramli ANM, Yusoff MM. Indole Alkaloids from Plants as Potential Leads for Antidepressant Drugs: A Mini Review. Front Pharmacol. 2017;8. doi: 10.3389/fphar.2017.00096. PubMed PMID: 28293192; PubMed Central PMCID: PMC5328930.

11. Obeng S, Kamble SH, Reeves ME, Restrepo LF, Patel A, Behnke M, et al. Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids. Journal of medicinal chemistry. 2020;63(1). doi: 10.1021/acs.jmedchem.9b01465. PubMed PMID: 31834797.

12. Boyer EW, Babu KM, Adkins JE, McCurdy CR, Halpern JH. Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction. 2008;103(6):1048-50. Epub 2008/05/17. doi: 10.1111/j.1360-0443.2008.02209.x. PubMed PMID: 18482427; PubMed Central PMCID: PMC3670991.

13. Matsumoto K, Mizowaki M, Suchittra T, Murakami Y, Takayama H, Sakai S, et al. Central antinociceptive effects of mitragynine in mice: contribution of descending noradrenergic and serotoninergic systems. Eur J Pharmacol. 1996;317(1):75-81. Epub 1996/12/12. PubMed PMID: 8982722.

14. Takayama H. Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa. Chem Pharm Bull (Tokyo). 2004;52(8):916-28. Epub 2004/08/12. PubMed PMID: 15304982.

15. Shimazaki Y, Yajima T, Takani M, Yamauchi O. Metal complexes involving indole rings: Structures and effects of metal–indole interactions. Coordination Chemistry Reviews. 2009;253(3):479-92. doi: https://doi.org/10.1016/j.ccr.2008.04.012.

16. Mantegani S, Brambilla E, Varasi M. Ergoline Derivatives: Receptor Affinity and Selectivity. Farmaco (Societa chimica italiana: 1989). 1999;54(5). doi: 10.1016/s0014-827x(99)00028-2. PubMed PMID: 10418123.

17. Vijayan Pillai K, Pandy V, Kunasegaran T, Murugan DD, Naidu M. Mitragyna speciosa Leaf Extract Exhibits Anti-psychotic-Like Effect with the Potential to Alleviate Positive and Negative Symptoms of Psychosis in Mice. Front Pharmacol. 2016;7:464. Epub 2016/12/22. doi: 10.3389/fphar.2016.00464. PubMed PMID: 27999544; PubMed Central PMCID: PMCPMC5138496.

18. Jia Y, Liu L, Sheng C, Cheng Z, Cui L, Li M, et al. Increased Serum Levels of Cortisol and Inflammatory Cytokines in People With Depression. The Journal of nervous and mental disease. 2019;207(4). doi: 10.1097/NMD.000000000000957. PubMed PMID: 30849440.

19. Kumarnsit E, Yongvatcharanon U, Keawpradub N, Intasaro P. Fos-like Immunoreactivity in Rat Dorsal Raphe Nuclei Induced by Alkaloid Extract of Mitragyna Speciosa. Neuroscience letters. 2007;416(2). doi: 10.1016/j.neulet.2007.01.061. PubMed PMID: 17316993.

20. Cheaha D, Keawpradub N, Sawangjaroen K, Phukpattaranoot P, Kumarnsit E. Effects of an Alkaloid-Rich Extract From Mitragyna Speciosa Leaves and Fluoxetine on Sleep Profiles, EEG Spectral Frequency and Ethanol Withdrawal Symptoms in Rats. Phytomedicine. 2015;22(11). doi: 10.1016/j.phymed.2015.07.008. PubMed PMID: 26407942.

21. Kumarnsit E, Keawpradub N, Nuankaew W. Effect of Mitragyna Speciosa Aqueous Extract on Ethanol Withdrawal Symptoms in Mice. Fitoterapia. 2007;78(3). doi: 10.1016/j.fitote.2006.11.012. PubMed PMID: 17335995.

22. Skuza G. Ethanol Withdrawal-Induced Depressive Symptoms in Animals and Therapeutic Potential of sigma1 Receptor Ligands. Pharmacological Rep. 2013;65(6). doi: 10.1016/s1734-1140(13)71530-5. PubMed PMID: 24553017.

23. Graziano S, Orsolini L, Rotolo MC, Tittarelli R, Schifano F, Pichini S. Herbal Highs: Review on Psychoactive Effects and Neuropharmacology. Curr Neuropharmacol. 2017;15(5):750-61. doi: 10.2174/1570159x14666161031144427. PubMed PMID: 27799032.

24. Grundmann O. Patterns of Kratom use and health impact in the US-Results from an online survey. Drug Alcohol Depend. 2017;176:63-70. Epub 2017/05/19. doi: 10.1016/j.drugalcdep.2017.03.007. PubMed PMID: 28521200.

25. Swogger MT, Hart E, Erowid F, Erowid E, Trabold N, Vijeepallam K, Pandy V, Kunasegaran T, Murugan DD, Naidu M. Mitragyna speciosa Leaf Extract Exhibits Anti-psychotic-Like Effect with the Potential to Alleviate Positive and Negative Symptoms of Psychosis in Mice. Front Pharmacol. 2016;7:464. Epub 2016/12/22. doi: 10.3389/fphar.2016.00464. PubMed PMID: 27999544; PubMed Central PMCID: PMCPMC5138496.

26. Smith KE, Lawson T. Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program. Drug Alcohol Depend. 2017;180:340-8. Epub 2017/09/28. doi: 10.1016/j.drugalcdep.2017.08.034. PubMed PMID: 28950240.

27. Coe MA, Pillitteri JL, Sembower MA, Gerlach KK, Henningsfield JE. Kratom as a Substitute for Opioids: Results
From an Online Survey. Drug and alcohol dependence. 2019;202. doi: 10.1016/j.drugalcdep.2019.05.005. PubMed PMID: 31284119.

28. Matsumoto K, Mizowaki M, Suchitra T, Takayama H, Sakai S, Aimi N, et al. Antinociceptive action of mitragynine in mice: evidence for the involvement of supraspinal opioid receptors. Life Sci. 1996;59(14):1149-55. Epub 1996/01/01. PubMed PMID: 8831802.

29. White CM. Pharmacologic and clinical assessment of kratom. Am J Health Syst Pharm. 2018;75(5):261-7. Epub 2017/12/20. doi: 10.2146/ajhp161035. PubMed PMID: 29255059.

30. Kruegel AC, Grundmann O. The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology. 2017. Epub 2017/08/24. doi: 10.1016/j.neuropharm.2017.08.026. PubMed PMID: 28830758.

31. Avery BA, Boddu SP, Sharma A, Furr EB, Leon F, Cutler SJ, et al. Comparative Pharmacokinetics of Mitragynine After Oral Administration of Mitragyna Speciosa (Kratom) Leaf Extracts in Rats. Planta medica. 2019;85(4). doi: 10.1055/a-0770-3683. PubMed PMID: 30452072.

32. Trakulsrichai S, Sathirakul K, Auparakkitanon S, Krongvorakul J, Sueajai J, Noumjad N, et al. Pharmacokinetics of mitragynine in man. Drug Des Devel Ther. 2015;9:2421-9. Epub 2015/05/23. doi: 10.2147/dddt.s79658. PubMed PMID: 25995615; PubMed Central PMCID: PMCP-mc4425236.

33. Rusli N, Amanah A, Kaur G, Adenan MI, Sulaiman SF, Wahab HA, et al. The inhibitory effects of mitragynine on P-glycoprotein in vitro. Naunyn Schmiedebergs Arch Pharmacol. 2019. Epub 2019/01/04. doi: 10.1007/s00210-018-01605-y. PubMed PMID: 30604191.

34. Reanmongkol W, Keawpradub N, Sawangjaroen K. Effects of the extracts from Mitragyna speciosa Korth. leaves on analgesic and behavioral activities in experimental animals. Songklanakarin J Sci Technol. 2007;29:39-48.

35. Sabetghadam A, Navaratnam V, Mansor SM. Dose–Response Relationship, Acute Toxicity, and Therapeutic Index between the Alkaloid Extract of Mitragyna speciosa and Its Main Active Compound Mitragynine in Mice. Drug Development Research. 2012;74(1):23-30. doi: https://doi.org/10.1002/ddr.21052.

36. Papsun DM, Chan-Hosokawa A, Friederich L, Brower J, Graf K, Logan B. The Trouble With Kratom: Analytical and Interpretative Issues Involving Mitragynine. Journal of analytical toxicology. 2019;43(8). doi: 10.1093/jat/bkz064. PubMed PMID: 31424079.

37. Suwanlert S. A study of kratom eaters in Thailand. Bull Narc. 1975;27(3):21-7. Epub 1975/07/01. PubMed PMID: 1041694.

38. Warner ML, Kaufman NC, Grundmann O. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. Int J Legal Med. 2016;130(1):127-38. Epub 2015/10/30. doi: 10.1007/s00414-015-1279-y. PubMed PMID: 26511390.